117 related articles for article (PubMed ID: 37306349)
1. The prognostic role of epidermal growth factor receptor mutation in completely resected ampullary adenocarcinoma.
Varol U; Cakır E; Aktas S; Altun ZS; Dilek FH; Butun O; Salman T; Unlu AGD; Alacacioglu A; Somali I
Pol J Pathol; 2023; 74(1):18-28. PubMed ID: 37306349
[TBL] [Abstract][Full Text] [Related]
2. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
3. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
[TBL] [Abstract][Full Text] [Related]
4. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
5. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater.
Ang DC; Shia J; Tang LH; Katabi N; Klimstra DS
Am J Surg Pathol; 2014 Oct; 38(10):1371-9. PubMed ID: 24832159
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
7. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
8. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.
Mikhitarian K; Pollen M; Zhao Z; Shyr Y; Merchant NB; Parikh A; Revetta F; Washington MK; Vnencak-Jones C; Shi C
Mod Pathol; 2014 May; 27(5):665-74. PubMed ID: 24186143
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
11. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
12. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
[TBL] [Abstract][Full Text] [Related]
13. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Classification of Ampullary Carcinomas: Critical Reappraisal Fails to Confirm Prognostic Relevance for Recently Proposed Panels, and Highlights MUC5AC as a Strong Prognosticator.
Xue Y; Reid MD; Balci S; Quigley B; Muraki T; Memis B; Xia J; Hacihasanoglu E; Bedolla G; Pehlivanoglu B; Kim GE; Tajiri T; Ohike N; Aneja R; Krasinskas AM; Adsay V
Am J Surg Pathol; 2017 Jul; 41(7):865-876. PubMed ID: 28505002
[TBL] [Abstract][Full Text] [Related]
16. Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer.
Park HM; Park SJ; Han SS; Hong SK; Hong EK; Kim SW
Medicine (Baltimore); 2019 Nov; 98(44):e17711. PubMed ID: 31689805
[TBL] [Abstract][Full Text] [Related]
17. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
19. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
Azuma K; Ota K; Kawahara A; Hattori S; Iwama E; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
Ann Oncol; 2014 Oct; 25(10):1935-1940. PubMed ID: 25009014
[TBL] [Abstract][Full Text] [Related]
20. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
